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The nosology of systemic sclerosis: how lessons from the 
past offer new challenges in reframing an idiopathic 
rheumatological disorder
Alain Lescoat*, Catherine Cavalin*, Rodney Ehrlich, Claire Cazalets, Alice Ballerie, Nicolas Belhomme, Guillaume Coiffier, Marine de Saint Riquier, 
Paul-André Rosental, Eric Hachulla, Vincent Sobanski, Patrick Jégo
Systemic sclerosis is a rare connective tissue disease characterised by a wide range of clinical manifestations. 
Compared with previous sets of criteria, the 2013 American College of Rheumatology and European League Against 
Rheumatism (ACR/EULAR) classification of systemic sclerosis encompasses a broader and more relevant spectrum 
of the condition. Nonetheless, clinical and prognostic heterogeneity persists among patients fulfilling these criteria. 
The next task in the classification of systemic sclerosis is the development of new subset criteria that can successfully 
identify subgroups of patients with distinct prognostic or pathophysiological features. In this Viewpoint we describe 
the history of systemic sclerosis over the past century with the objective of highlighting the effect of previous 
nosological debates on efforts to understand and manage this disorder. Rather than seeking to present a systematic 
review of possible subgrouping for systemic sclerosis in relation to prognosis, we aim to clarify how nosological 
considerations have influenced our understanding of the cause and prognosis of this so-called idiopathic 
rheumatological disorder and how aetiological, prognostic, and pathophysiological hypotheses have helped to describe 
clusters within the disease. By reflecting on past nosological debates and endeavours, we identify challenges for the 
current initiative to develop a new subgrouping of systemic sclerosis.
Introduction
Nosology—the definition and naming of disease entities—
has long been a subject at the boundary between the 
management of pathological conditions and the his tory of 
medical and biological knowledge.1 Among other issues, 
two are crucial in defining disease entities: the aetiological 
and pathophysiological bases of nosological entities (a 
given nosological entity is usually associated with a given 
set of causes); and the practical implications for research 
and clinical practice of subdivision of a condition into 
subsets or clusters.2
The debate about reframing and renaming non-
communicable diseases (NCDs) initiated by Allen 
and Feigl3 in The Lancet Global Health reminds us that 
a name change or a new definition can galvanise the 
re-conceptualisation of an entire condition, with far-
reaching consequences. For example, in offering a clear 
con sensual definition for idiopathic pulmonary fibrosis 
and a better description of non-specific interstitial pneu-
monia, the updated 2013 definition of idiopathic inter stitial 
pneumonia4 has offered an opportunity to improve the 
understanding of the mechanisms underlying the patho-
genesis of these disorders. It has also enabled anti fibrotic 
therapies to be adapted for the proper clusters of patients, 
on the basis of CT results and clinical considerations, thus 
allowing substantial progress in the management of 
idiopathic pulmonary fibrosis.
In the field of rheumatology, systemic sclerosis can be 
considered a typical rheumatological NCD, a chronic and 
severe disorder of complex and unknown cause.5 The 
history of its nosology illustrates the great con sequences of 
naming and classification. The multiple subgroup ings 
and names of systemic sclerosis over time have shaped 
aetiological and prognostic hypotheses successively 
proposed for this systemic disorder and, alternatively, com-
or bidities such as cancers associated with systemic 
sclerosis, have helped to adapt the management of specific 
subgroups of patients.
A new international clustering initiative for systemic 
sclerosis is being developed to determine the most use-
ful subgrouping within the entity defined by the 2013 
American College of Rheumatology and European League 
Against Rheumatism (ACR/EULAR) classifica tion.6–10 
Using an historical perspective, this Viewpoint aims 
to clarify how nosological considerations of systemic 
sclerosis have influenced our understanding of the aetio-
logy and prognosis of this so-called idiopathic rheuma-
tological disorder and the way aetiological, prognostic, and 
pathophysio logical hypotheses have conversely helped to 
highlight clusters within the disease, and to discuss the 
prospect of a new subgrouping enriching our view of 
systemic sclerosis.
Acrosclerosis, scleroderma, and systemic 
sclerosis: nosological shifts around a rare 
autoimmune disorder
In the early 1900s scleroderma (at that time mostly 
spelled sclerodermia) was mostly understood as a 
dermatological disorder. Hutchinson11 highlighted the 
difference between morphea (localised scleroderma) and 
diffuse scleroderma or acrosclero derma (previously 
spelled acrosclerodermia), pointing out the unusual 
frequent association of acro scleroderma with the vascular 
changes observed in Raynaud’s disease.12 Morphea or 
localised scleroderma was therefore separated very early 
on from other forms of scleroderma (figure 1). Separately, 
from a strictly derma tological point of view, without any 
visceral considera tions, a distinction was made among 
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the sclerodermas: acrosclerosis on the one hand, defining 
the association of sclero dactyly (or dermatosclerosis) 
with distal vascular changes, and a rapidly spreading 
sclero derma with gen eral ised cutaneous involvement 
and a poorer prognosis on the other.13,14
Sellei13 and then O’Leary and Waisman14 assumed 
acrosclerosis to be a unique disease, and not simply the 
coincidental co-occurrence of Raynaud’s syndrome 
with sclerodactyly. Ingram15 also stressed the necessity 
of making a clear distinction between acrosclerosis or 
distal vascular scleroderma, and diffuse or generalised 
scleroderma which did not begin on fingers but on wrists 
and was more aggressive.16 The clear recognition of these 
two distinct nosological conditions also coincided with 
the definitive loss of the “i” from the name. At first, the 
analysis of the visceral involvement seemed to re-enforce 
the difference between acrosclerosis and generalised or 
diffuse scleroderma. O’Leary and Waisman14 highlighted 
the different prognosis of these two clusters, pointing 
out that acrosclerosis affected predominantly women, 
and was associated with Raynaud’s phenomenon, visceral 
lesions, and a good prognosis.
By contrast, generalised or diffuse scleroderma affected 
both sexes, was less associated with Raynaud’s phenom-
enon, had a poorer prognosis, and, paradoxically, visceral 
lesions were initially thought to be rare.17 Gastrointestinal 
lesions were specifically noticed in acro sclerosis at the 
beginning of the twentieth century,18–20 and only later on in 
generalised scleroderma.21 Heart involvement was care-
fully documented by Goetz22 in 1951 in generalised 
scleroderma. Lloyd and Tonkin23 enriched the literature on 
pulmonary fibrosis. Given these obser vations on visceral 
lesions, a shift in the controversy on scleroderma cluster-
ing emerged; if visceral involvement tends to be similar in 
acrosclerosis and generalised scleroderma, should these 
conditions be reunited under the same name?
In 1959, Jablonska and colleagues16 did a systematic 
analysis of vascular changes, skin involvement, and, 
most importantly, visceral changes in 45 patients with 
scleroderma. Their explicit objective was to prove that 
acrosclerosis was a subgroup of scleroderma with marked 
vascular changes but not a disease in its own right. They 
concluded that acrosclerosis was a variety of diffuse 
scleroderma (ie, in contrast with morphea or localised 
scleroderma) preceded or accompanied by Raynaud’s 
phenomenon. In almost all cases there were simultaneous 
features of both so-called acrosclerosis and diffuse 
scleroderma, which made a clear distinction between the 
two diseases impossible. They noted that “generalisation 
of the sclerotic changes in the skin occur in any case of 
scleroderma, including those which begin in the hands 
and are preceded or accompanied by Raynaud’s phenom-
enon”.16 Therefore, the terms scleroderma, acrosclerosis, 
or sclerodactyly became apparent misnomers24 that no 
longer adequately described the whole picture of the 
condition.17 As the term sclerosis was already in use, the 
name systemic sclerosis, as first suggested by Goetz,19 
was endorsed, stressing the possible severe visceral 
manifestations of the disease and including the internal 
organ involvement in the very name of the disorder.
Consensual views of the disease for research 
purposes and early diagnosis
A tentative but persistent distinction remained between a 
slowly spreading systemic sclerosis, which shared fea-
tures with the previously named acrosclerosis, and a 
rapidly progressive condition with a poorer prognosis 
named progressive systemic sclerosis.22 Nevertheless, 
since the 1960s most authors considered systemic scler-
osis and progressive systemic sclerosis to be the same 
entity encompassing the outdated acro sclerosis and the 
generalised scleroderma.25
The conceptual shift from perceiving scleroderma as a 
dermatological disorder to perceiving it as a systemic 
condition with a wide spectrum of clinical presenta tions, 
allowed the emer gence of a new entity (figure 2). In 1962, 
Rodnan and Fennell26 reported four patients with systemic 
sclerosis with visceral involvement (digestive, myo cardial, 
Figure 1: Naming flow of sclerodermas and systemic sclerosis over the past century
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or lung lesions) but with no evidence of skin fibrosis, 
thereby enriching the systemic sclerosis nomenclature with 
the concept of systemic sclerosis sine scleroderma. This 
understanding of the disease as a systemic disorder also 
coincided with the identifica tion of autoanti bodies, with 
focus on antinucleolar anti bodies.27 In 1968, Rothfield and 
Rodnan28 showed that the specific pattern of fluorescence of 
antinuclear anti bodies could help to confirm the clinical 
diagnosis of systemic sclerosis. In 1980, Moroi and col-
leagues29 brought to light anticentromere anti bodies and 
their frequent associ ation with a variant of systemic 
sclerosis, the Calcinosis-Raynaud phenomenon-Esophageal 
dysmotility-Sclerodactyly-Telangiectasia (known as CREST), 
which was first des cribed by Winterbauer30 in the English 
liter ature,30,31 inherited from a 1910 observa tion by Thibièrge 
and Weissenbach.32 
In 1980, Masi and colleagues from the Subcommittee for 
Scleroderma Criteria of the American Rheumatism 
Committee25,33 proposed standardised clinical classifi cation 
criteria with the objective of establishing a consensus on 
inclusion criteria, to enable compari son between groups of 
patients from different centres, especially for research 
purposes. A consensual classifi cation of the disease was 
therefore adopted, including proximal scleroderma (sclero-
derma tous skin changes proximal to the metacarpo-
phalangeal or metatar so phalangeal joints) as a major 
(sufficient) criterion, or at least two of the three minor 
criteria: bibasal pulmonary fibrosis, digital pitting scars, 
and sclerodactyly. This clinical picture was further refined 
in 1988 by LeRoy and colleagues,34 who reintroduced 
a skin-driven sub grouping of diffuse versus limited 
cutaneous systemic sclerosis,34 on the basis of prognostic 
considerations in longitudinal studies,35 while maintaining 
the under standing of the subgroups as parts of a unique 
but heterogeneous disease. The concept of an intermediate 
cutaneous systemic scler osis was proposed by Giordano 
and colleagues35 but was finally not adopted. Another 
skin-driven subgrouping was suggested by Barnett and 
colleagues,36 separating three types of systemic sclerosis 
depending on the extent of fibrosis (figure 2). The dichoto-
mous sub grouping proposed by LeRoy and colleagues34 in 
1988 was finally preferred to other approaches, including 
CREST, which were abandoned.
As early management of visceral involvement and 
treatment were believed to improve survival rates, in 2001 
LeRoy and Medsger37 proposed the concept of early 
systemic sclerosis, on the basis of the association of the 
hallmark feature of Raynaud’s phenomenon with a 
scleroderma-type nailfold capillary pattern or scleroderma 
selective antibodies. This concept of early systemic scler-
osis introduced the pre-scleroderma stage of limited 
systemic sclerosis, that differed from limited cutan-
eous systemic sclerosis by the absence of cutaneous 
involve ment. It also differed from Rodnan and Fennell’s26 
1962 systemic sclerosis sine scleroderma, which involved 
visceral manifestations of the disease even in the absence 
of cutaneous changes.38 In 2011, Avouac and colleagues39 
of the European Scleroderma Trials And Research 
(EUSTAR) group went further by defining a core set of 
preliminary criteria necessary for a very early diagnosis of 
systemic sclerosis on the basis of Raynaud’s phenomenon, 
puffy fingers or antinuclear antibodies. They thus strati-
fied the risk of developing systemic sclerosis on the basis 
of the results of capillaroscopic findings and more specific 
immunological investigations. This new approach for the 
diagnosis of systemic sclerosis allowed a more informed 
follow-up of patients who were most at risk of developing 
this systemic disorder. Nonetheless, a system atic early 
diagnosis could also lead to misinterpreta tion, as some 
patients might never develop authentic systemic sclerosis, 
with subsequent anxiety among patients and an increased 
cost of screening.
In 2013, the ACR and the EULAR established a 
committee to provide a joint proposal for new classifi-
cation criteria for systemic sclerosis.6 Their objective was 
to develop criteria that could include both patients in the 
Figure 2: Skin-derived clustering of systemic sclerosis 
The limited versus diffuse cutaneous systemic sclerosis subsets (D and G) as proposed by LeRoy are currently the most widely used skin-driven sub-classification.
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early and late stages of the disease. These new criteria 
integrated vascular, immunological, and fibrotic mani-
festations and were established as feasible in daily 
practice. They were also far more sensitive and specific 
than the previous 1980 ACR classification criteria.
Each of these definitions, and each new naming of the 
disease accompanying them, has influenced research 
on the possible causes of systemic sclerosis in the past 
hundred years and, conversely, prognostic considerations, 
more refined clinical phenotyping, better characterisation 
of autoantibody status, and some aetiological hypotheses 
have served to highlight specific subgroups, influencing 
nosology and management (figure 3).
Nosology and its effect on the search for the 
cause of systemic sclerosis
Exposure to crystalline silica is now identified as an 
environmental risk factor for systemic sclerosis. None-
theless, the gradual emergence of this understanding 
depended on the changing nosological boundaries of 
the disease. In 1914, Bramwell,40 a Scottish physician in 
Edinburgh, UK, published a case series of nine patients 
with diffuse scleroderma. Bramwell stressed the rarity of 
the condition and its unusually frequent occurrence in 
stonemasons. For the first time, diffuse scleroderma 
was thus addressed as an occupational, environmentally 
driven condition. As the name of the disease was the 
misnomer (scleroderma), with the disease being still 
widely accepted as a dermatological disorder (figure 1), the 
intriguing high prevalence of scleroderma in stonemasons 
directed the search for causes towards a skin-mediated 
process. Although Bramwell observed the onset of the 
disease in the stonemasons’ hands, he emphasised the 
holding of chisels or hammers during cold weather as 
a possible cause for the disease. He made no mention 
of silica exposure, even though we can assume that 
stonemasons had both cutaneous and respiratory expos-
ure to crystalline silica particles during stone-cutting. 
More over, five of the nine patients presented by Bramwell 
were stonemasons, and one was a coal miner, another 
occupation exposed to silica inhalation. Bramwell con-
sidered scleroderma as a dermatological condition. He 
noticed no systemic mani festation nor any visceral 
involve ment, especially no lung involvement, except for 
pleurisy and pneumonia in one patient.
By contrast, in 1957 Erasmus41 examined the incidence 
of scleroderma in South African underground mine-
workers, with a specific interest in pulmonary manifes-
tations in a historical and local context, in which 
respiratory occupational health was of primary concern. 
From the beginning, Erasmus stressed the importance of 
properly naming the disease. He deplored the ambiguity 
of the term scleroderma, and insisted on the terms 
generalised or diffuse scleroderma to denote that “internal 
organs as well as skin [were] involved in the disease 
process”. Considering scleroderma as a systemic disease 
with pulmonary involvement coexisting with features of 
silicosis in underground gold miners, Erasmus proposed 
the hypothesis that mining was a predisposing or 
precipitating factor for systemic sclerosis. He recognised 
the importance of the work that Bramwell did in 1914 as 
the first occupational lens on the disease, but he also 
highlighted the role of silica dust exposure on Bramwell’s 
patients. From the 1957 publication emerged the entity of 
Erasmus syndrome, characterising the association of 
systemic sclerosis and crystalline silica exposure with or 
without silicosis. Since the late 1970s, studies have also 
hypothesised that other environmental and occupational 
exposures, such as solvents, might constitute risk factors 
for developing systemic sclerosis.42
A paradigm shift in the late 1960s to viewing systemic 
sclerosis as an auto-immune disorder, linked to the 
Figure 3: From the history of the nosology and understanding of systemic sclerosis to the current debate on a new subgrouping strategy
RNA pol III=anti-RNA polymerase III antibodies. dcSSc=diffuse cutaneous systemic sclerosis. SRC=scleroderma renal crisis. ATA=antitopoisomerase antibodies. 
ILD=interstitial lung disease. *The association of anticentromere antibodies (ACA) with pulmonary arterial hypertension (PAH) is less concordant in the literature 
than their association with limited cutaneous systemic sclerosis (lcSSc).
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production of autoantibodies targeting autoantigens, 
further shaped our view of its aetiology and management 
(figure 3). Immunological studies from the past decade 
have revealed cases of anti-RNA polymerase III anti bodies 
associated with synchronous neoplasia at the time of 
diagnosis of systemic sclerosis.43 These results have 
been confirmed epidemiologically,44 and the underlying 
molecular mechanisms have been clarified thanks to 
fundamental and translational research showing specific 
targeting of tumour antigens by these autoantibodies. 
Both highlighting this specific association and revealing a 
subgroup that some would consider as paraneoplastic 
systemic sclerosis have changed the standard of care for 
these patients. These findings have resulted in calls for 
systematic screening for cancers in patients recently 
diagnosed with systemic sclerosis who are positive for 
anti-RNA polymerase III antibodies, although the preval-
ence of cancers remains low even in this subgroup.
Beyond cancers, the association between anti-RNA 
polymerase III antibodies and scleroderma renal crisis 
has influenced the standard of care for this subgroup of 
patients.45 Careful automonitoring of arterial pressure has 
been recommended for these patients to detect any early 
sign of scleroderma renal crisis, which would require the 
introduction of angiotensin-converting enzyme inhibitors 
that can dramatically improve the prognosis of these 
patients.46,47 Considering systemic sclerosis as an auto-
immune disorder has also paved the way for genetic 
studies identifying susceptibility loci as risk factors for 
developing the disease, with a specific interest in genes 
involved in the regulation of adaptive and innate immun-
ity.48 In summary, the emergence of new antibodies since 
the identification of antinuclear antibodies in patients 
with systemic sclerosis, and their association with clinical 
features, have allowed for new clustering strategies.8,49
Systemic sclerosis subgroups: the challenge of 
diversifying evaluation tools and clustering 
strategies
In 2015, Pope50 suggested that new subset criteria within 
the ACR/EULAR 2013 classification should be developed, 
stressing the constraints of the dichotomous limited 
versus diffuse view of the disease, noting that patients with 
early limited cutaneous systemic sclerosis could evolve to a 
diffuse cutaneous systemic sclerosis and that skin fibrosis 
in diffuse cutaneous systemic sclerosis could regress. In 
2015, Ligon and Wigley51 argued that focusing on skin 
manifestations alone clearly missed essential features of 
the disease process, such as serological biomarkers, other 
organ involvement, and the rapidity of disease progression. 
They suggested that the limited versus diffuse subsets 
from LeRoy’s 1988 subgrouping strategy, constituted 
a “black and white” view of systemic sclerosis whereas a 
“tech nicolor”, ie, a more subtle and hetero geneous char-
acterisa tion of the disorder, would be more accurate. Using 
a qualitative content analytic approach, Johnson and col-
leagues8 also stressed the necessity of a new sub grouping 
and synthesised the views of international systemic 
sclerosis experts on the main challenges and objectives of 
these upcoming new subsets of systemic sclerosis. Three 
thematic areas arose from this analysis. First, the new 
clusters should help to directly improve management of 
patients with systemic sclerosis who require treatment, 
early investigation, and monitoring over time. Second, the 
new subgrouping should be designed as a research and 
communication tool, allowing for a reduction in hetero-
geneity of the disease by improving sample selection 
and offering a more accurate view of the disease to edu-
cate patients, trainees, and health-care professionals. 
Finally, the challenge for this new sub grouping would 
be to improve the correlation between disease subsets 
and prognosis, in terms of survival and internal organ 
involvement.8,50
With respect to these considerations, none of the 
previous subgroupings of systemic sclerosis included 
gender in the clustering design. Studies based on the 
largest worldwide multicentre cohort of the EUSTAR 
group have confirmed that the disease appears to be strik-
ingly more severe in men.52 Although systemic sclerosis is 
more common in women, men affected by the condition 
have a higher risk of severe cardiovascular involvement. 
Thus, we are encouraged to maintain a greater awareness 
of gender in the clinical decision-making process.
Exploring this gender gap also entails broadening the 
field of research on systemic sclerosis. As men and 
women experience distinct exposures (eg, solvents, 
silica dust) because of occupational and possibly extra-
occupational activities, the gender difference in systemic 
sclerosis might be explained once we gain a better under-
standing of the pathophysiological processes involved in 
toxicant-associated autoimmunity. A gendered approach 
to aetiology could also benefit from evalua tion tools 
borrowed from the social sciences (eg, quantitative survey 
research and ethnographic approaches). These tools could 
provide a better knowledge of potential environmental 
risk factors and social determinants. As argued in 
The Lancet, proper reporting of sex and gender should be 
an important task for medical research in general.53–55 
Shim56 urges us to rethink the epidemiological multi-
factorial model, which dominates this discipline, to 
highlight differences between and within subpopulations 
affected by chronic diseases. Among other differences, sex 
and gender deserve not to be addressed as black boxes 
(ie, entities to be taken for granted) but, on the contrary, 
questioned to understand their internal mechanisms.57 
The general considerations raised by Shim on epidemi-
ological variables, usually handled as patients’ individual 
characteristics, urge us to investigate how differences 
between women and men are produced in systemic 
sclerosis and “what exactly about…sex/gender contributes 
to [this] chronic disease”.56 Of course, inclusion of gender 
in a new clustering of systemic sclerosis should not lead to 
an oversimplified dichotomous black and white view of 
the disease.51 The relationship between sex and gender 
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and systemic sclerosis is likely to be more complex than it 
seems, especially considering that diffuse cutaneous 
systemic sclerosis and antitopoisomerase antibodies tend 
to be more frequent in men. In a 2019 EUSTAR 
study exploring phenotype-driven hierarchical clustering, 
cluster C1 in the study, which had the lowest prevalence of 
men (6%), showed the best survival, whereas cluster C6 
with the highest prevalence of men (21%) had the worst 
survival, stressing that even in more subtle clustering 
analyses, sex and gender still influence prognosis, and 
further deciphering the possible multiple reasons behind 
these results remains challenging.9 Integrating sex and 
gender in a hierarchical approach with autoantibodies and 
cutaneous subsets might also help to explore this issue.
In a similar vein, cohort studies evaluating the adverse 
prognosis of scleroderma among African Americans, 
have shown the importance of socioeconomic status and 
socioeconomic determinants of health (marital status, 
education, employment, health insurance status) as 
independent predictors of systemic sclerosis severity, 
independent of race. These studies showed that in this 
idiopathic disorder social determinants are of interest 
alongside clinical, serological, and genetic predictors.58,59 
Considering the reframing of NCDs suggested by Allen 
and Feigl3, Vijayasingham and Allotey60 proposed a 
conceptual extension. If gender, social factors, and, in the 
case of systemic sclerosis, environmental factors and 
coassociated NCDs, such as synchronous cancer in some 
anti-RNA polymerase III antibody-related sclerodermas, 
affect the onset of the disease, these factors might also 
influence scleroderma’s course and severity, and the 
patient’s quality of life.
Autoantibodies, which contributed to conceptualising 
systemic sclerosis as one disease in the late 1960s,28 
remain a cornerstone in the debate surrounding the 
upcoming subgrouping of systemic sclerosis.8,59,51 The pro-
gressive identification of antibody patterns associated with 
an increased risk of specific visceral involvement, has 
offered new diversity among patients with systemic 
sclerosis: the association of anti-RNA polymerase III 
antibodies with scleroderma renal crisis and with diffuse 
cutaneous systemic sclerosis,45,49 or that of anticentromere 
antibodies with limited cutaneous systemic sclerosis and 
with a possible increased risk of pulmonary arterial 
hypertension.61 There is also evidence for increased risk of 
interstitial lung disease in patients with antitopoisomerase 
antibodies, anti-U11/U12 RNP antibodies, or anti-Th/To 
antibodies (figure 3).51,61–63 Therefore a more refined pheno-
typing of patients and better characterisation of the 
relationship between autoantibody profile and prognosis 
might be needed.63 As each antibody subtype usually 
excludes others, from a practical viewpoint, an antibody-
based hierarchical clustering associated with other 
parameters such as skin involvement might appear 
convenient.8,49,63 However, a cluster analysis of the EUSTAR 
database showed that serological heterogeneity existed 
within apparently homogeneous clinical clusters.9 As 
clinical subsets and antibodies have been found to be 
variable on the basis of genetic background, generalisation 
of an antibody-based clustering might have some limits. 
Nonetheless, clinical trials such as the successful random-
ised placebo-controlled SENSCIS trial,64 evalu ating the 
efficacy and safety of nintedanib in systemic sclerosis-
associated interstitial lung disease and its ability to reduce 
the decline of forced vital capacity, included a stratification 
based on antitopoisomerase antibodies in its randomisa-
tion strategy. This inclusion shows that antibody status 
is a practical and relevant way to define homogeneous 
groups among patients with systemic sclerosis, especially 
for clinical trials.
Conclusion
In 1903, at an early stage in the nosological history of 
systemic sclerosis, Nixon65 argued that “one likes…to 
minimise the points of contrast between one patient and 
another, and to bring out into high relief the similarities, 
so that the final triumph may be achieved of labelling a 
new disease with a new name, and suggesting a new 
preparation…as the new remedy”. Although tinted with 
slight irony, this statement illustrates the close association 
of systemic sclerosis clustering with therapeutics. Until 
now, none of the previous subgroupings of this dis-
ease were shaped with direct therapeutic considerations 
in mind. Thera peutic trials nowadays still use the old 
skin-driven, diffuse versus limited cutaneous systemic 
sclerosis subgrouping in their inclusion criteria (figure 2), 
although many of them also endeavour to refine this 
approach by adding limitations on the basis of minimal or 
maximal fibrosis skin score values, specific disease course-
based sub groups (eg, early vs late systemic sclerosis), or 
like the SENSCIS trial, antibody status.64,66 Using these not 
fully endorsed subgroup definitions might help to produce 
new cluster strategies and reinforce the association 
between subgroups within systemic sclerosis and thera-
peutic considerations. In the SENSCIS trial, the authors 
discussed the effect of including patients with limited 
cutaneous systemic sclerosis, which might have led to a 
smaller annual rate of decline in forced vital capacity than 
assumed in the sample size calculation. Although the trial 
produced a positive result, bringing some optimism to the 
future management of systemic scler osis, this statement 
from the paper’s authors shows that even in trials based 
on single organ impairment (in this case, pulmonary 
involvement), the question of clustering matters.64
The best methods to define the new subgrouping are 
still a matter of debate. Methodological breakthroughs 
and innovative subgrouping techniques have emerged 
and include principal component analysis based on 
autoantibody status and titres,7,63 machine learning-based 
phenotype-driven hierarchical clustering,9 and systemic 
sclerosis subsets based on molecular patterns, gene 
expression profiles, and combined omics technologies 
from the perspective of personalised medicine.10,67,68 These 
approaches could accelerate progress by successfully 
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identifying subgroups of patients with distinct prognosis 
or pathophysiological processes, beyond the dichotomous 
skin-driven sub-grouping that still lingers in 2019. 
However, these approaches need to be synthesised or 
combined to shape practical and easy-to-use subsets of 
systemic sclerosis as there is also a risk of building too 
complex or inapplicable clustering. Whatever the final 
form, the new subgrouping of systemic sclerosis is 
needed as a lever to ensure that this poorly understood 
condition earns the attention it deserves.
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